Immuneering (NASDAQ:IMRX) CEO Benjamin Zeskind Buys 2,400 Shares

Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin Zeskind bought 2,400 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The stock was purchased at an average cost of $4.56 per share, for a total transaction of $10,944.00. Following the completion of the acquisition, the chief executive officer owned 2,315,252 shares in the company, valued at $10,557,549.12. This trade represents a 0.10% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Immuneering Stock Performance

Immuneering stock opened at $4.60 on Thursday. Immuneering Corporation has a 52 week low of $2.87 and a 52 week high of $10.08. The stock has a market capitalization of $297.62 million, a P/E ratio of -3.93 and a beta of 0.38. The stock has a 50-day simple moving average of $4.99 and a 200 day simple moving average of $5.26.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. Research analysts forecast that Immuneering Corporation will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On Immuneering

Institutional investors have recently made changes to their positions in the stock. Empery Asset Management LP bought a new position in Immuneering during the 4th quarter worth $17,601,000. State Street Corp lifted its position in shares of Immuneering by 1,289.7% during the 4th quarter. State Street Corp now owns 2,402,238 shares of the company’s stock valued at $15,807,000 after acquiring an additional 2,229,374 shares during the period. Vanguard Group Inc. lifted its position in shares of Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock valued at $16,907,000 after acquiring an additional 1,358,322 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Immuneering during the 3rd quarter worth $6,602,000. Finally, Blue Owl Capital Holdings LP acquired a new stake in shares of Immuneering during the 3rd quarter worth $3,850,000. 67.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IMRX has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Immuneering in a report on Monday, March 9th. Chardan Capital restated a “buy” rating and issued a $20.00 price target on shares of Immuneering in a research note on Tuesday, May 19th. Oppenheimer reaffirmed an “outperform” rating on shares of Immuneering in a report on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research report on Friday, March 27th. Finally, Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.